Ozempic cut risk of death in diabetes patients with chronic kidney disease; Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical

Taking stock of the drug industry, from the lab to the medicine chest

May 24, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

SEBASTIEN BOZON/AFP via Getty Images STAT+ | Ozempic cut risk of death in diabetes patients with chronic kidney disease New data suggest the blockbuster drug may offer some added benefits over other classes of therapies approved to treat this population. By Elaine Chen STAT+ | Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. By Allison DeAngelis STAT+ | FDA advisers endorse Guardant Health's colon cancer screening test Guardant Health's blood-based colon cancer detection test was endorsed for FDA approval by an independent panel of advisers. By Angus Chen and Jonathan Wosen Molly Ferguson for STAT STAT+ | After MDMA therapy, she considered suicide. The trial data tell a different story FDA urged to probe claims of underreported adverse events in Lykos Therapeutics trials of psychedelic therapy for PTSD. By Olivia Goldhill

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser